# Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT02254239** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Everolimus
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02254239
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-04
- **Primary completion:** 2018-12-12
- **Final completion:** 2018-12-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** funding withdrawal
- **Last updated:** 2019-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254239, "Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02254239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*